GB9827604D0 - Methods of immunosuppression - Google Patents

Methods of immunosuppression

Info

Publication number
GB9827604D0
GB9827604D0 GBGB9827604.1A GB9827604A GB9827604D0 GB 9827604 D0 GB9827604 D0 GB 9827604D0 GB 9827604 A GB9827604 A GB 9827604A GB 9827604 D0 GB9827604 D0 GB 9827604D0
Authority
GB
United Kingdom
Prior art keywords
immunosuppression
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9827604.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Ltd
Original Assignee
Lorantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lorantis Ltd filed Critical Lorantis Ltd
Priority to GBGB9827604.1A priority Critical patent/GB9827604D0/en
Publication of GB9827604D0 publication Critical patent/GB9827604D0/en
Priority to EP99961206A priority patent/EP1141243A2/en
Priority to JP2000588338A priority patent/JP2002532086A/en
Priority to PCT/GB1999/004233 priority patent/WO2000036089A2/en
Priority to AU17895/00A priority patent/AU768236B2/en
Priority to NZ512412A priority patent/NZ512412A/en
Priority to CA002354147A priority patent/CA2354147A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB9827604.1A 1998-12-15 1998-12-15 Methods of immunosuppression Ceased GB9827604D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB9827604.1A GB9827604D0 (en) 1998-12-15 1998-12-15 Methods of immunosuppression
EP99961206A EP1141243A2 (en) 1998-12-15 1999-12-15 Methods of immunosuppression
JP2000588338A JP2002532086A (en) 1998-12-15 1999-12-15 Immunosuppression method
PCT/GB1999/004233 WO2000036089A2 (en) 1998-12-15 1999-12-15 Methods of immunosuppression
AU17895/00A AU768236B2 (en) 1998-12-15 1999-12-15 Methods of immunosuppression
NZ512412A NZ512412A (en) 1998-12-15 1999-12-15 Methods of immunosuppression
CA002354147A CA2354147A1 (en) 1998-12-15 1999-12-15 Methods of immunosuppression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9827604.1A GB9827604D0 (en) 1998-12-15 1998-12-15 Methods of immunosuppression

Publications (1)

Publication Number Publication Date
GB9827604D0 true GB9827604D0 (en) 1999-02-10

Family

ID=10844262

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9827604.1A Ceased GB9827604D0 (en) 1998-12-15 1998-12-15 Methods of immunosuppression

Country Status (7)

Country Link
EP (1) EP1141243A2 (en)
JP (1) JP2002532086A (en)
AU (1) AU768236B2 (en)
CA (1) CA2354147A1 (en)
GB (1) GB9827604D0 (en)
NZ (1) NZ512412A (en)
WO (1) WO2000036089A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB0019242D0 (en) * 2000-08-04 2000-09-27 Lorantis Ltd Assay
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
JP2004536877A (en) * 2001-07-25 2004-12-09 ロランティス リミテッド Notch signaling modulators for immunotherapy
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
GB0220658D0 (en) * 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
AU2003269268A1 (en) * 2002-10-09 2004-05-04 Lorantis Limited Modulation of immune function
GB0300428D0 (en) * 2003-01-09 2003-02-05 Lorantis Ltd Medical treatment
JP2006517533A (en) * 2003-01-23 2006-07-27 ロランティス リミテッド Treatment of autoimmune diseases using activators of the Notch signaling pathway
WO2004082710A1 (en) * 2003-03-21 2004-09-30 Lorantis Limited Treatment of allergic diseases using a modulator of the notch signaling pathway
GB0307472D0 (en) * 2003-04-01 2003-05-07 Lorantis Ltd Medical treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
CN1172718C (en) * 1995-10-04 2004-10-27 依默耐克斯有限公司 Dendritic cell stimulatory factor
CN1160371C (en) * 1996-11-07 2004-08-04 洛伦蒂斯有限公司 NOTCH protein and their ligands

Also Published As

Publication number Publication date
EP1141243A2 (en) 2001-10-10
JP2002532086A (en) 2002-10-02
AU1789500A (en) 2000-07-03
WO2000036089A3 (en) 2000-10-26
CA2354147A1 (en) 2000-06-22
NZ512412A (en) 2004-04-30
WO2000036089A2 (en) 2000-06-22
AU768236B2 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
GB9717766D0 (en) Methods
EP1033994A4 (en) Methods of preparation of bioginkgo
GB9622665D0 (en) Methods
GB9708918D0 (en) Methods
GB9827604D0 (en) Methods of immunosuppression
IL143562A0 (en) Immunosuppression
GB9707742D0 (en) Methods
GB9718591D0 (en) Methods
GB9602704D0 (en) Structure of perculator
GB2343104B (en) Carrying aid
GB9803322D0 (en) Methods
ZA985543B (en) Novel methods
TW444662U (en) Improved structure of clamp
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
GB9827921D0 (en) Immunosuppression
GB9826168D0 (en) Immunosuppression
GB9705301D0 (en) Method of switching
TW339135U (en) Oil-injection insulation ring
TW328252U (en) Improved structure of pliers
TW354479U (en) Improvement of earpick
TW398188U (en) Improved structure of de-hooker
TW306561U (en) Improved structure of wind-stopping block
TW304520U (en) Improved structure of groyne
GB9813912D0 (en) Methods
GB9827407D0 (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)